Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas

Klaudyna Fidyt, Marta Krawczyk, Monika Pepek, Katsiaryna Marhelava, Agnieszka Kraft, Malgorzata Bobrowicz, Aleksandra Kusowska, Joanna Barankiewicz, Przemyslaw Juszczynski, Michal Smida, Myron Czuczman, Francisco Hernandez-Ilizaliturri, Malgorzata Firczuk, Magdalena Winiarska

Blood (2022) 140 (Supplement 1): 10273–10274.

https://doi.org/10.1182/blood-2022-162292

Published: 2022

Journal Articles

Enhanced Anti-Tumor Activity with Exposure to BCL-2 and BRD4 Inhibitors in Mantle Cell Lymphoma

Kevin Bowman, Cory Mavis, Taylor K Mandeville, Noah Lemoine, Juan Gu, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 8850.

https://doi.org/10.1182/blood-2022-169438

Published: 2022

Journal Articles

Targeting BCL-XL to Overcome Anti-CD20 Antibodies and Venetoclax Resistance in Pre-Clinical Model of Diffuse Large B Cell Lymphoma

Juan J. Gu, Jessica Wang, Cory Mavis, Taylor K Mandeville, Pallawi Torka, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 11562–11563.

https://doi.org/10.1182/blood-2022-159120

Published: 2022

Journal Articles

PLX51107 Enhances the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia When Combined with Venetoclax

Cory Mavis, Kevin Zablonski, Suchitra Sundaram, Juan Gu, Pallawi Torka, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 12357–12358.

https://doi.org/10.1182/blood-2022-169123

Published: 2022

Journal Articles

Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax

Taylor Mandeville, Cory Mavis, Juan Gu, Noah Lemoine, Kevin Bowman, Scott Olejniczak, Prasenjit Dey, Gyorgy Paragh, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 7398–7399.

https://doi.org/10.1182/blood-2022-170436

Published: 2022

Journal Articles

Iron Deficiency Is Commonly Observed in Female Multiple Sclerosis (MS) Patients with Relapsed/Refractory or Primary Progressive Disease Referred for Biological Therapies

Sarah Patel, Rajat Thawani, Thomas G. Deloughery, Vijayshree Yadav, Francisco Hernandez-Ilizaliturri, Merav Sendowski

Blood (2022) 140 (Supplement 1): 11086–11087.

https://doi.org/10.1182/blood-2022-170573

Published: 2022

Journal Articles

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Blood (2022) 140 (Supplement 1): 10391–10393.

https://doi.org/10.1182/blood-2022-159725

Published: 2022

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Manali Kamdar

Blood (2022) 140 (Supplement 1): 1581–1583.

https://doi.org/10.1182/blood-2022-159702

Published: 2022

Journal Articles

Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis

Sheeba Ba Aqeel, Othman Salim Akhtar, Arya Mariam Roy, Alankrita Taneja, Richa Parikh, Muhammad Salman Faisal, Hassan Awada, Andrea Anampa-Guzman, Matthew J Cortese, Francisco Hernandez-Ilizaliturri, Pallawi Torka

Blood (2022) 140 (Supplement 1): 5172–5173.

https://doi.org/10.1182/blood-2022-168164

Published: 2022

Journal Articles

Effect of Mcl-1 Inhibitor, AMG-176, on T Cell Quality and Function

Noah Lemoine, Taylor K Mandeville, Cory Mavis, Kevin Bowman, Juan J. Gu, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 12706–12707.

https://doi.org/10.1182/blood-2022-170122

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 9368–9372.

https://doi.org/10.1182/blood-2022-159425

Published: 2022

Journal Articles

Evaluation of Antibody and T Cell Responses to COVID-19 Vaccination in Patients with Lymphoid Malignancies Receiving B Cell-Depleting Agents

Shipra Goel, Brahm Segal, Elizabeth A. Griffiths, Francisco Hernandez-Ilizaliturri, Pallawi Torka, Matthew J Cortese, Paola Ghione, Michael J. Nemeth, Jason Muhitch

Blood (2022) 140 (Supplement 1): 6468–6469.

https://doi.org/10.1182/blood-2022-170369

Published: 2022

Journal Articles

The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)

Othman Salim Akhtar, Andrea Anampa-Guzman, Matthew J Cortese, Alankrita Taneja, Sheeba Ba Aqeel, Paola Ghione, Francisco Hernandez-Ilizaliturri, Pallawi Torka

Blood (2022) 140 (Supplement 1): 5160–5161.

https://doi.org/10.1182/blood-2022-167826

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 2316–2320.

https://doi.org/10.1182/blood-2022-159497

Published: 2022

Journal Articles

Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome

Blood (2014) 124 (21): 1703.

https://doi.org/10.1182/blood.V124.21.1703.1703

Published: 2014

Journal Articles

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Natalie M. Czuczman, BSc, Sarah Frys, BSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 647.

https://doi.org/10.1182/blood.V122.21.647.647

Published: 2013

Journal Articles

Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models.

Matthew J. Barth, MD, Gopichand Pendurti, MD, Ping-Chiao Tsai, PhD, Cory Mavis, BSc, MSc, Pavel Klener, Jr., Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2012) 120 (21): 2757.

https://doi.org/10.1182/blood.V120.21.2757.2757

Published: 2012

Journal Articles

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors

Sarah Frys, BSc, Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Juan Gu, PhD, John Gibbs, MD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2012) 120 (21): 1649.

https://doi.org/10.1182/blood.V120.21.1649.1649

Published: 2012

Journal Articles

Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL)

Juan Gu, PhD, Francisco Hernandez-Ilizaliturri, MD, Gregory P. Kaufman, Cory Mavis, BSc, MSc, Myron S. Czuczman, MD

Blood (2012) 120 (21): 1655.

https://doi.org/10.1182/blood.V120.21.1655.1655

Published: 2012

NARROW

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas

Enhanced Anti-Tumor Activity with Exposure to BCL-2 and BRD4 Inhibitors in Mantle Cell Lymphoma

Targeting BCL-XL to Overcome Anti-CD20 Antibodies and Venetoclax Resistance in Pre-Clinical Model of Diffuse Large B Cell Lymphoma

PLX51107 Enhances the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia When Combined with Venetoclax

Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax

Iron Deficiency Is Commonly Observed in Female Multiple Sclerosis (MS) Patients with Relapsed/Refractory or Primary Progressive Disease Referred for Biological Therapies

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis

Effect of Mcl-1 Inhibitor, AMG-176, on T Cell Quality and Function

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Evaluation of Antibody and T Cell Responses to COVID-19 Vaccination in Patients with Lymphoid Malignancies Receiving B Cell-Depleting Agents

The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models.

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors

Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only